Stock listing
NASDAQ:ERNA Ernexa Therapeutics Inc. Stock
Home listing (NASDAQ) of Ernexa Therapeutics Inc.
Follow Ernexa Therapeutics Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ERNA
$1.36 USD -0.26 (-16.0%)
Close on Nov 20, 2026
- Day range
- $1.35 – $1.60 USDNov 20, 2026
- Volume
- 20,382 sharesNov 20, 2026
- Market cap
- $2.30M USDAt the close on Nov 20, 2026 · price × 1.69M shares outstanding
- 52-week range
- $1.35 – $37.50 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $140,241 USDMedian day 20,382 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ERNA · Home | $1.36 USD | -0.26 (-16.0%) | 20,382 | $1.60 | $1.60 | $1.35 | $1.62 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ERNA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.36 | -0.26 | -16.0% | $1.60 | $1.60 | $1.35 | 20,382 | |
| $1.62 | -0.01 | -0.6% | $1.64 | $1.713 | $1.60 | 14,752 | |
| $1.63 | -0.06 | -3.6% | $1.65 | $1.822 | $1.57 | 26,221 | |
| $1.69 | +0.01 | +0.6% | $1.80 | $1.80 | $1.69 | 20,359 | |
| $1.68 | -0.11 | -6.1% | $1.82 | $1.94 | $1.67 | 28,254 | |
| $1.79 | -0.14 | -7.3% | $1.87 | $2.04 | $1.734 | 23,989 | |
| $1.93 | -0.08 | -4.0% | $2.053 | $2.053 | $1.90 | 9,815 | |
| $2.01 | -0.04 | -2.0% | $1.98 | $2.04 | $1.90 | 13,321 | |
| $2.05 | +0.17 | +9.0% | $1.87 | $2.05 | $1.755 | 28,402 | |
| $1.88 | +0.05 | +2.7% | $1.78 | $1.895 | $1.78 | 7,913 | |
| $1.83 | -0.16 | -8.0% | $2.05 | $2.05 | $1.74 | 33,732 | |
| $1.99 | -0.03 | -1.5% | $1.98 | $2.04 | $1.94 | 17,332 | |
| $2.02 | +0.07 | +3.6% | $2.075 | $2.123 | $1.99 | 11,368 | |
| $1.95 | -0.02 | -1.0% | $2.04 | $2.04 | $1.93 | 8,999 | |
| $1.97 | -0.14 | -6.6% | $2.08 | $2.14 | $1.95 | 4,493 | |
| $2.11 | +0.13 | +6.6% | $2.03 | $2.11 | $1.998 | 7,265 | |
| $1.98 | -0.013 | -0.7% | $1.91 | $2.03 | $1.91 | 3,471 | |
| $1.993 | +0.055 | +2.8% | $2.12 | $2.12 | $1.96 | 7,436 | |
| $1.938 | -0.127 | -6.2% | $1.98 | $2.08 | $1.92 | 11,182 | |
| $2.065 | -0.01 | -0.5% | $2.075 | $2.09 | $2.03 | 5,931 | |
| $2.075 | -0.035 | -1.7% | $2.095 | $2.125 | $1.98 | 16,467 | |
| $2.11 | -0.13 | -5.8% | $2.19 | $2.255 | $2.08 | 9,569 | |
| $2.24 | +0.26 | +13.1% | $1.96 | $2.26 | $1.89 | 48,186 | |
| $1.98 | -0.11 | -5.3% | $2.04 | $2.07 | $1.839 | 44,353 | |
| $2.09 | -0.08 | -3.7% | $2.17 | $2.23 | $2.04 | 24,617 | |
| $2.17 | +0.06 | +2.8% | $2.10 | $2.23 | $2.05 | 7,004 | |
| $2.11 | -0.10 | -4.5% | $2.20 | $2.20 | $2.013 | 10,300 | |
| $2.21 | 0.00 | 0.0% | $2.19 | $2.24 | $2.18 | 8,312 | |
| $2.21 | -0.19 | -7.9% | $2.40 | $2.40 | $2.125 | 30,705 | |
| $2.40 | -0.09 | -3.6% | $2.45 | $2.49 | $2.25 | 46,599 | |
| $2.49 | +0.10 | +4.2% | $2.40 | $2.70 | $2.12 | 214,740 | |
| $2.39 | +0.155 | +6.9% | $2.25 | $2.39 | $2.15 | 662,923 | |
| $2.235 | -0.465 | -17.2% | $2.75 | $2.96 | $2.20 | 91,550 | |
| $2.70 | -0.26 | -8.8% | $3.04 | $3.058 | $2.70 | 21,552 | |
| $2.96 | 0.00 | 0.0% | $3.00 | $3.28 | $2.90 | 40,810 | |
| $2.96 | -0.24 | -7.5% | $3.13 | $3.236 | $2.84 | 35,741 | |
| $3.20 | +0.04 | +1.3% | $3.24 | $3.47 | $3.16 | 42,635 | |
| $3.16 | -0.31 | -8.9% | $3.738 | $3.738 | $3.044 | 61,865 | |
| $3.47 | +0.025 | +0.7% | $3.46 | $3.50 | $3.20 | 25,791 | |
| $3.445 | -0.175 | -4.8% | $3.73 | $3.848 | $3.40 | 21,417 | |
| $3.62 | -0.03 | -0.8% | $3.785 | $3.821 | $3.61 | 11,526 | |
| $3.65 | -0.15 | -3.9% | $3.73 | $3.79 | $3.65 | 6,237 | |
| $3.80 | -0.16 | -4.0% | $3.96 | $3.96 | $3.76 | 14,663 | |
| $3.96 | +0.13 | +3.4% | $4.01 | $4.01 | $3.75 | 13,500 | |
| $3.83 | +0.07 | +1.9% | $3.79 | $3.885 | $3.79 | 8,276 | |
| $3.76 | -0.15 | -3.8% | $4.04 | $4.08 | $3.715 | 33,601 | |
| $3.91 | -0.17 | -4.2% | $4.01 | $4.155 | $3.84 | 22,562 | |
| $4.08 | -0.19 | -4.4% | $3.79 | $4.70 | $3.65 | 547,184 | |
| $4.27 | +0.105 | +2.5% | $4.13 | $4.40 | $4.13 | 16,826 | |
| $4.165 | +0.145 | +3.6% | $4.05 | $4.42 | $4.03 | 19,816 | |
| $4.02 | 0.00 | 0.0% | $3.925 | $4.05 | $3.90 | 11,381 | |
| $4.02 | -0.17 | -4.1% | $4.20 | $4.23 | $3.97 | 15,648 | |
| $4.19 | -0.12 | -2.8% | $4.31 | $4.34 | $4.13 | 18,298 | |
| $4.31 | -0.22 | -4.9% | $4.50 | $4.83 | $4.21 | 47,568 | |
| $4.53 | -0.01 | -0.2% | $4.494 | $4.728 | $4.40 | 14,673 | |
| $4.54 | +0.19 | +4.4% | $4.42 | $4.804 | $4.40 | 23,297 | |
| $4.35 | -0.22 | -4.8% | $4.57 | $4.65 | $4.26 | 29,517 | |
| $4.57 | 0.00 | 0.0% | $4.68 | $4.75 | $4.54 | 9,638 | |
| $4.57 | -0.165 | -3.5% | $4.76 | $4.99 | $4.56 | 26,720 | |
| $4.735 | -0.155 | -3.2% | $4.77 | $4.93 | $4.56 | 41,081 | |
| $4.89 | -0.035 | -0.7% | $4.82 | $4.932 | $4.75 | 15,092 | |
| $4.925 | -0.11 | -2.2% | $5.00 | $5.51 | $4.894 | 81,862 | |
| $5.035 | +0.175 | +3.6% | $4.86 | $5.15 | $4.75 | 22,643 | |
| $4.86 | +0.34 | +7.5% | $4.53 | $5.198 | $4.53 | 71,125 | |
| $4.52 | +0.09 | +2.0% | $4.34 | $4.76 | $4.34 | 27,832 |
Splits
4 splits since 2021 · NASDAQ:ERNA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-25 | Consolidation | |
| 1-for-15 | Consolidation | |
| 1-for-20 | Consolidation | |
| 1-for-2 | Consolidation |
- Ticker
- NASDAQ:ERNA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 22, 2026
Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment
Latest deck · Oct 15, 2026
Investor Presentation (October 2026)
Investor deck · 19 slides
Latest news
Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment
Oct 22, 2026
Closed $2.08 (-1.7%) on Oct 22, 2026
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
Oct 12, 2026
Closed $2.21 (0.0%) on Oct 13, 2026
Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center
Oct 6, 2026
Closed $2.24 (-17.2%) on Oct 6, 2026
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
Oct 1, 2026
Closed $2.96 (-7.5%) on Oct 1, 2026
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
Sep 30, 2026
Closed $3.20 (+1.3%) on Sep 30, 2026
Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy
Sep 29, 2026
Closed $3.16 (-8.9%) on Sep 29, 2026
Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors
Sep 17, 2026
Closed $3.76 (-3.8%) on Sep 17, 2026
Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Sep 14, 2026
Closed $4.27 (+2.5%) on Sep 14, 2026
Initial Statement of Beneficial Ownership (Form 3)
Aug 28, 2026
Closed $4.57 (-3.5%) on Aug 28, 2026
Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
Aug 27, 2026
Closed $4.74 (-3.2%) on Aug 27, 2026
Ernexa Therapeutics Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 27 in the last 12 months · 72 in all · newest Oct 22, 2026 · oldest 2022
- Decks
- 12 decks · latest Oct 15, 2026
Where Ernexa Therapeutics Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ERNA · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ERNA | BOATS | United States | USD |
Valuation
Price/book 0.5× against a median of 0.4×: 6th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$2.96M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 0.86
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Ernexa Therapeutics Inc. · NASDAQ:ERNA | US$2.30M | −US$2.96M | n/a | n/a | n/a | 0.5× | n/a | 0.1× | 0.86 |
| ValiRx PLC · LSE:VAL | US$2.42M | US$1.15M | n/a | 28.0× | n/a | 0.6× | n/a | 0.0× | n/a |
| BSF Enterprise PLC · LSE:BSFA | US$2.40M | US$2.95M | n/a | 42.7× | n/a | 1.0× | n/a | 0.3× | n/a |
| Revelation Biosciences, Inc. · NASDAQ:REVB | US$2.39M | −US$5.92M | n/a | n/a | n/a | 0.3× | n/a | 0.1× | 1.66 |
| Mustang Bio, Inc. · NASDAQ:MBIO | US$2.38M | −US$11.89M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 1.01 |
| Quest PharmaTech Inc. · TSXV:QPT | US$2.36M | US$2.30M | 0.7× | n/a | n/a | 0.1× | n/a | 0.0× | 1.90 |
| HCW Biologics Inc. · NASDAQ:HCWB | US$2.35M | US$8.23M | n/a | 1.2× | n/a | 0.3× | −63.4% | 1.0× | 1.19 |
| Cynata Therapeutics Limited · ASX:CYP | US$2.26M | US$1.66M | n/a | 1.5× | n/a | n/a | −540.4% | n/a | n/a |
| PharmaCyte Biotech, Inc. · NASDAQ:PMCB | US$2.25M | −US$15.59M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.97 |
| Modus Therapeutics Holding AB · OMXSTO:MODTX | US$2.22M | US$1.00M | n/a | n/a | n/a | 2.2× | n/a | 0.0× | n/a |
| Nuformix PLC · LSE:NFX | US$2.22M | US$1.00M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | n/a |
| Median of the others | US$2.36M | US$1.08M | 0.7× | 14.7× | 0.4× | −301.9% | 0.0× | 1.66 |
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 9, 2026. Not 6ix's view and not investment advice.
- Price target
- 30.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -18.02 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Sanjeev Luther | President and CEO |
| Mark J. Keeley | Chief Financial Officer |
| Dorothy Clarke | General Counsel |
| Deborah Wild | Head of CMC and Operations |
| Marc C. Chamberlain | Chief Medical Officer |
| Robert Pierce | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| James Bristol | Chairman |
| Bill Wexler | Director |
| David Polinsky | Director |
| Elena Ratner | Director |
| Peter Cicala | Director |
| Robert J. Spiegel | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 6, 2026 · After close | +9.0% |
| Q2 2026 | Aug 12, 2026 | −2.0% |
| Q1 2026 | May 11, 2026 · After close | +66.6% |
| Q4 2025 | Mar 24, 2026 | −10.4% |
| Q3 2025 | Nov 7, 2025 | −1.2% |
| Q2 2025 | Aug 13, 2025 | −4.1% |
| Q1 2025 | May 7, 2025 | −3.9% |
| Q4 2024 | Mar 12, 2025 | −4.9% |
| Q3 2024 | Nov 29, 2024 | −9.1% |
| Q2 2024 | Aug 12, 2024 | +4.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 22, 2024 | −5.4% |
| Q4 2023 | Mar 19, 2024 | −6.0% |
| Q3 2023 | Nov 13, 2023 · Before open | −2.5% |
| Q2 2023 | Aug 11, 2023 · After close | −0.4% |
| Q1 2023 | May 11, 2023 · After close | −2.3% |
| Q4 2022 | Mar 20, 2023 · Before open | −7.7% |
| Q3 2022 | Nov 14, 2022 · After close | −1.1% |
| Q2 2022 | Aug 11, 2022 · After close | +2.6% |
| Q1 2022 | Apr 15, 2022 · After close | −11.6% |
| Quarter to Sep 30, 2021 | Nov 12, 2021 · After close | −0.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 19 slides | Oct 15, 2026 |
| Investor Presentation (October 2026) | Investor deck | 19 slides | Oct 15, 2026 |
| Investor Presentation (September 2026) | Investor deck | 17 slides | September 2026 |
| Investor Presentation (July 2026) | Investor deck | 24 slides | Jul 2, 2026 |
| Investor Presentation (February 2026) | Investor deck | 33 slides | Feb 26, 2026 |
| Investor Presentation (December 2025) | Investor deck | 31 slides | Dec 11, 2025 |
| Eterna Therapeutics — Investor Presentation (August 2023) | Investor deck | 18 slides | Aug 2, 2023 |
| Eterna Therapeutics — Investor Presentation (November 2022) | Investor deck | 15 slides | Nov 9, 2022 |
| Brooklyn ImmunoTherapeutics — Investor Presentation (November 2021) | Investor deck | 30 slides | Nov 12, 2021 |
| Brooklyn ImmunoTherapeutics — Investor Presentation (September 2021) | Investor deck | 21 slides | Sep 20, 2021 |
All 12 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Brooklyn ImmunoTherapeutics — Investor Presentation (September 2021) | Investor deck | 9 slides | Sep 9, 2021 |
| Brooklyn ImmunoTherapeutics — Merger or Acquisition (July 2021) | Merger or acquisition | 13 slides | Jul 19, 2021 |
Financings
| Raise | Date |
|---|---|
| Public offering of shares of common stock (or common stock equivalents) and accompanying warrants Announced: about US$10.5M · US$0.5 a share · Warrants at US$0.68 · Brookline Capital Markets, a division of Arcadia Securities, LLC Dealers: Brookline Capital Markets, a division of Arcadia Securities, LLC (lead) Use of proceeds: Advancement of its development programs, working capital and general corporate purposes | Feb 6, 2026 |
| Private placement of shares of common stock and pre-funded warrants Tranche closed: US$7.1M raised · US$0.1046 a share Use of proceeds: General working capital and repayment of certain notes | Jun 24, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 582.0K | 68.0K | 0 | 0 | 5.80M | 19.8M | 23.3M | 21.3M | 22.3M |
| Cost of revenue | 263.0K | 96.0K | 236.0K | 0 | 459.0K | 98.0K | 7.84M | 8.38M | 7.09M | 8.13M |
| Gross profit | -263.0K | 486.0K | -168.0K | 0 | -459.0K | -98.0K | 12.0M | 14.9M | 14.2M | 14.2M |
| Research and development | 4.16M | 4.60M | 5.92M | 10.4M | 12.7M | 2.00K | 26.0K | 72.0K | 139.0K | |
| Selling, general and administrative | 5.16M | 13.1M | 14.6M | 16.6M | 14.7M | 8.09M | 13.2M | 14.5M | 15.6M | 16.5M |
| Operating income | -9.32M | -15.7M | -21.1M | -33.2M | -113.7M | -7.25M | -1.76M | 203.0K | -1.40M | -2.28M |
| Depreciation and amortization | 65.0K | 139.0K | 84.0K | 161.0K | 117.0K | 98.0K | 2.88M | 2.76M | 2.32M | 2.89M |
| EBITDA | -9.25M | -15.5M | -21.1M | -33.1M | -113.6M | -7.15M | 1.11M | 2.97M | 915.0K | 609.0K |
| Interest expense | -100.0K | -6.80M | 614.0K | 30.0K | 74.0K | 118.0K | 236.0K | 296.0K | 425.0K | 517.0K |
| Income before tax | -14.1M | -44.5M | -21.7M | -24.5M | -122.5M | -7.29M | -2.02M | -323.0K | -1.01M | -2.88M |
| Income tax | -45.0K | 30.0K | -3.00K | 45.0K | 64.0K | 0 | 27.0K | -64.0K | 66.0K | 38.0K |
| Net income | -14.1M | -44.5M | -21.7M | -24.6M | -122.5M | -7.29M | -2.05M | -259.0K | -1.08M | -2.92M |
| Earnings per share, basic | -2.24 | -48.96 | -4.08 | -8.06 | -56.61 | -0.41 | -0.72 | -0.10 | -0.45 | -1.54 |
| Earnings per share, diluted | -2.24 | -48.96 | -4.08 | -8.06 | -56.61 | -0.41 | -0.72 | -0.10 | -0.45 | -1.54 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.88M | 1.73M | 7.58M | 11.4M | 17.0M | 777.0K | 3.21M | 2.54M | 3.38M | 5.69M |
| Receivables | 95.0K | 437.0K | 425.0K | 951.0K | 684.0K | 0 | 1.20M | 1.14M | 714.0K | 928.0K |
| Inventory | -951.0K | -116.0K | 1.09M | 2.54M | 4.87M | 3.00M | ||||
| Current assets | 3.13M | 2.35M | 9.60M | 13.7M | 18.8M | 1.73M | 6.07M | 6.79M | 9.64M | 10.7M |
| Property, plant and equipment | 94.0K | 85.0K | 493.0K | 236.0K | 670.0K | 594.0K | 2.82M | 4.67M | 3.68M | 3.10M |
| Goodwill | 2.04M | 2.04M | 2.04M | 2.04M | 2.04M | 2.04M | 696.0K | 667.0K | 1.00M | 937.0K |
| Total assets | 5.83M | 5.27M | 49.1M | 22.3M | 31.5M | 12.9M | 14.1M | 14.9M | 16.6M | 16.7M |
| Accounts payable | 1.13M | 1.72M | 1.07M | 1.62M | 1.75M | 1.27M | 835.0K | 271.0K | 390.0K | 247.0K |
| Current liabilities | 3.11M | 2.94M | 6.57M | 7.65M | 3.68M | 3.13M | 6.09M | 4.02M | 10.7M | 6.64M |
| Long-term debt | 6.77M | 1.21M | 532.0K | |||||||
| Total debt | 490.0K | 684.0K | 41.8M | 4.14M | 2.72M | 2.03M | 2.74M | 3.75M | 5.12M | 8.11M |
| Total liabilities | 3.43M | 3.57M | 46.9M | 10.2M | 6.02M | 5.25M | 9.03M | 7.95M | 11.0M | 12.6M |
| Shareholders' equity | 2.40M | 1.70M | 2.23M | 12.1M | 25.5M | 7.66M | 9.74M | 6.92M | 5.54M | 4.07M |
| Shares outstanding | 314.0K | 3.43M | 5.41M | 5.13M | 2.60M | 0 | 2.90M | 2.88M | 2.52M | 2.26M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -7.02M | -15.8M | -20.4M | -21.0M | -23.5M | -8.10M | 2.74M | 1.36M | 549.0K | 23.0K |
| Capital spending | -37.0K | -369.0K | -19.0K | -297.0K | -154.0K | -39.0K | -128.0K | -648.0K | -728.0K | -427.0K |
| Free cash flow | -7.05M | -16.2M | -20.4M | -21.3M | -23.6M | -8.14M | 2.62M | 717.0K | -179.0K | -404.0K |
| Cash from investing | -37.0K | -365.0K | -19.0K | -47.0K | -22.7M | -39.0K | -1.06M | -1.58M | -1.45M | -840.0K |
| Cash from financing | 7.21M | 6.26M | 16.6M | 19.6M | 61.6M | 4.67M | -1.10M | -303.0K | -1.47M | 3.26M |
| Dividends paid | -16.0K | -16.0K | -16.0K | -8.00K | -16.0K | -16.0K | -16.0K | -16.0K | -16.0K | |
| Share buybacks | -16.3M | -22.9M | 35.0K | |||||||
| Change in cash | 155.0K | -9.94M | -3.87M | -1.44M | 15.4M | -2.63M | 623.0K | -592.0K | -2.37M | 2.44M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 19, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 10, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 30, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 15, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Sep 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 16, 2026 | Current report | SEC |
| 8-K · Current report | Sep 16, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 27, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 2, 2026 | Current report | SEC |
| 8-K · Current report | Jul 2, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jun 26, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 20, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | May 11, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | May 11, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 11, 2026 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 4, 2026 | Current report | SEC |
| DEF 14C | Apr 13, 2026 | Meeting notice | SEC |
| PRE 14C | Apr 1, 2026 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Mar 31, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 26, 2026 | Other filings | SEC |
| S-3/A · Registration statement, amended | Mar 24, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 20, 2026 | Current report | SEC |
| UPLOAD · Letter from the SEC | Mar 20, 2026 | Other filings | SEC |
| S-3 · Registration statement | Mar 13, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 13, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2026 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 11, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Feb 10, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Feb 6, 2026 | Other filings | SEC |
| CERT · Exchange's certificate of listing | Feb 5, 2026 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Feb 5, 2026 | Other filings | SEC |
| S-1/A · Registration statement, amended | Feb 5, 2026 | Offer document | SEC |
| S-1/A · Registration statement, amended | Feb 3, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Feb 3, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 3, 2026 | Other filings | SEC |
| S-1 · Registration statement | Feb 2, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 19, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 16, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 11, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 7, 2025 | Quarterly report | SEC |
| DRSLTR · Letter to the SEC with a draft | Oct 22, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Oct 22, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 18, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 7, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jun 20, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Jun 18, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jun 16, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 16, 2025 | Other filings | SEC |
| 8-K · Current report | Jun 12, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 11, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jun 11, 2025 | Offer document | SEC |
| S-3 · Registration statement | Jun 11, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 9, 2025 | Financing | SEC |
| 8-K · Current report | Jun 2, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 7, 2025 | Quarterly report | SEC |
| 4/A · Change in ownership, amended | May 7, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Apr 30, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Apr 29, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 25, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 25, 2025 | Other filings | SEC |
| S-3 · Registration statement | Apr 16, 2025 | Offer document | SEC |
| ARS · Annual report to shareholders | Apr 14, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 14, 2025 | Meeting notice | SEC |
| D | Apr 11, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 4, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 4, 2025 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Apr 3, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 3, 2025 | Material contract | SEC |
| 8-K · Current report | Mar 26, 2025 | Current report | SEC |
| 8-K · Current report | Mar 24, 2025 | Material contract | SEC |
| 10-K · Annual report | Mar 12, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2025 | Material contract | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 5, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 13, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 28, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 14, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 10, 2025 | Management or board change | SEC |
| 8-K · Current report | Jan 3, 2025 | Current report | SEC |
| 424B3 · Prospectus | Nov 18, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Nov 18, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Nov 18, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Nov 18, 2024 | Other filings | SEC |
| D | Nov 14, 2024 | Other filings | SEC |
| D | Nov 14, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 13, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 13, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| S-1 · Registration statement | Nov 5, 2024 | Offer document | SEC |
| 4 · Change in ownership | Nov 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 29, 2024 | Material contract | SEC |
| ARS · Annual report to shareholders | Oct 16, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Oct 7, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Sep 27, 2024 | Meeting notice | SEC |
| 8-K · Current report | Sep 27, 2024 | Material contract | SEC |
| 8-K · Current report | Sep 25, 2024 | Material contract | SEC |
| 8-K · Current report | Sep 23, 2024 | Current report | SEC |
| 8-K · Current report | Aug 19, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Jun 25, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Apr 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 22, 2024 | Current report | SEC |
| 10-K/A · Annual report, amended | Mar 18, 2024 | Annual report | SEC |
| 10-K · Annual report | Mar 14, 2024 | Annual report | SEC |
| 3 · Initial statement of ownership | Feb 16, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 16, 2024 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 31, 2024 | Big-stake notice | SEC |
| 424B3 · Prospectus | Jan 24, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 23, 2024 | Other filings | SEC |
| 8-K · Current report | Jan 19, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 19, 2024 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | Jan 18, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 17, 2024 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Jan 16, 2024 | Offer document | SEC |
| S-3 · Registration statement | Jan 12, 2024 | Offer document | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 3, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Dec 22, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Dec 20, 2023 | Material contract | SEC |
| SC 13G · Big-stake notice | Dec 20, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 20, 2023 | Insider trade | SEC |
| D | Dec 19, 2023 | Other filings | SEC |
| 4 · Change in ownership | Dec 18, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 14, 2023 | Material contract | SEC |
| 8-K · Current report | Nov 16, 2023 | Material contract | SEC |
| 3 · Initial statement of ownership | Nov 13, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 13, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 1, 2023 | Management or board change | SEC |
| 8-K · Current report | Oct 5, 2023 | Management or board change | SEC |
| 8-K/A · Current report, amended | Sep 26, 2023 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Sep 8, 2023 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 7, 2023 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Sep 1, 2023 | Insider trade | SEC |
| 8-K · Current report | Aug 31, 2023 | Management or board change | SEC |
| SC 13G · Big-stake notice | Aug 28, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 25, 2023 | Insider trade | SEC |
| 424B3 · Prospectus | Aug 23, 2023 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Aug 23, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 18, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 17, 2023 | Other filings | SEC |
| S-3 · Registration statement | Aug 14, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 11, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 10, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 10, 2023 | Insider trade | SEC |
| 8-K · Current report | Aug 10, 2023 | Management or board change | SEC |
| 8-K · Current report | Aug 2, 2023 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Jul 26, 2023 | Big-stake notice | SEC |
| D | Jul 26, 2023 | Other filings | SEC |
| D | Jul 26, 2023 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 20, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2023 | Insider trade | SEC |
| 8-K · Current report | Jul 18, 2023 | Material contract | SEC |
| 4 · Change in ownership | Jul 18, 2023 | Insider trade | SEC |
| 8-K · Current report | Jul 13, 2023 | Material contract | SEC |
| 3 · Initial statement of ownership | Jul 11, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 11, 2023 | Insider trade | SEC |
| 8-K · Current report | Jul 11, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Jun 23, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 20, 2023 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 11, 2023 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | May 9, 2023 | Meeting notice | SEC |
| ARS · Annual report to shareholders | May 5, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | May 5, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 5, 2023 | Meeting notice | SEC |
This page holds 200 of 1,001 filings. Open Filings
Cap table
Built by 6ix from Ernexa Therapeutics Inc.’s releases · as of Nov 6, 2026
- Common shares
- 1,692,550
- Fully diluted
- 1,692,550
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 1,692,550 | Nov 6, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 1,692,550 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Robert J. Spiegel Other companies: RenovoRx, Inc. (Director · Since at least Apr 25, 2023); Geron Corporation (Director · Since at least Sep 29, 2017); Athenex Inc (Director · Aug 4, 2020 – Apr 21, 2023 · Past); Ayala Pharmaceuticals Inc (Director · May 7, 2020 – Jan 19, 2023 · Past); Bio Green Med Solution, Inc. (Director · Sep 6, 2018 – Jun 30, 2023 · Past); PDS Biotechnology Corporation (Director · Jun 19, 2018 – Mar 15, 2019 · Past); Sucampo Pharmaceuticals Inc (Director · Feb 13, 2018 – Feb 13, 2018 · Past) | Director · Since at least Sep 14, 2026 |
| Dennis Langer Other companies: Quoin Pharmaceuticals. Ltd (Director · Since at least Jan 1, 2023); Pernix Therapeutics Holdings Inc (Director · Nov 4, 2016 – May 22, 2018 · Past); Delcath Systems, Inc. (Director · Dec 11, 2014 – Jun 10, 2015 · Past); Dicerna Pharmaceuticals Inc (Director · Sep 24, 2013 – Jun 20, 2019 · Past); Myrexis Inc (Director · Dec 8, 2011 – Dec 8, 2011 · Past); Myriad Genetics, Inc. (Director · Dec 2, 2011 – Jun 30, 2022 · Past) | Director · May 1, 2021 – Dec 8, 2021 · Past |
| James Bristol Other companies: Erasca, Inc. (Director · Since at least Jan 1, 2024); Deciphera Pharmaceuticals LLC (Director · Jun 11, 2024 – Jun 11, 2024 · Past) | Chairman · Since at least Oct 30, 2023 |
| Luba Greenwood Other companies: IN8bio, Inc. (Director · Since at least Jul 29, 2021); Traws Pharma, Inc. (Director · Sep 16, 2024 – Sep 16, 2024 · Past) | Director · Mar 25, 2021 – Dec 8, 2021 · Past |
| Charles Cherington Other companies: Beard Energy Transition Acquisition Corp (Director · Nov 23, 2021 – Nov 23, 2021 · Past) | Director · Mar 25, 2021 – Dec 2, 2022 · Past |
| David Polinsky Other companies: Rafael Holdings, Inc. (Chief Financial Officer · Since at least Oct 25, 2023) | Director · Since at least Aug 4, 2026 |
| Erin S Enright Other companies: Amarin Corporation plc (Director · May 16, 2022 – Jun 27, 2022 · Past) | Director · Jan 14, 2022 – Jan 14, 2022 · Past |
| Matthew Angel Other companies: Tempest Therapeutics, Inc. (CEO and President, Director · Since at least Feb 3, 2026) | President and CEO, Director · May 26, 2022 – Jan 12, 2023 · Past |
| Roger Sidhu Other companies: Cardiff Oncology, Inc. (Chief Medical Officer · Since at least Jun 16, 2025) | Chief Medical Officer · Sep 20, 2021 – Sep 20, 2022 · Past |
| Bill Wexler | Director · Since at least Nov 4, 2026 |
All 40 people
| Person | Seat |
|---|---|
| Brant Binder | Director · Jul 6, 2023 – Jul 14, 2023 · Past |
| Christopher Allen George | Chief Information Officer · Aug 6, 2012 – Aug 6, 2012 · Past |
| C Kirk Read | Director · Sep 13, 2007 – Sep 13, 2007 · Past |
| Deborah Wild | Head of CMC and Operations · Since at least Nov 5, 2026 |
| Dorothy Clarke | General Counsel · Since at least Nov 5, 2026 |
| Elena Ratner | Director · Since at least May 20, 2026 |
| George P Denny III | Director · Mar 25, 2021 – Mar 25, 2021 · Past |
| Gregory Fiore | Director · Jun 5, 2022 – Aug 1, 2022 · Past |
| Gregory Matthew Thomas | Director · Jun 7, 2019 – Jun 7, 2019 · Past |
| Jay Sial | Chief Administration Officer · Jul 15, 2021 – Mar 11, 2022 · Past |
| John Gaffney | Sr. V.P. Product Management · Feb 1, 2008 – Feb 4, 2008 · Past |
| Joseph J Farricielli Jr | Director · Dec 18, 2007 – Jun 15, 2009 · Past |
| Kartik V Ramachandran | Chief Strat Off, EVP Bus Dev · Apr 24, 2009 – Apr 24, 2009 · Past |
| Kevin DAmour | Chief Scientific Officer · Jun 28, 2021 – Jun 28, 2022 · Past |
| Kirk Nagamine | Chief Revenue Officer · Apr 15, 2013 – Apr 15, 2013 · Past |
| Lynn Sadowski Mason | See Remarks · Mar 25, 2021 – Mar 25, 2021 · Past |
| Marc C. Chamberlain | Chief Medical Officer · Since at least Nov 5, 2026 |
| Mariana Danilovic | Ex. VP, Business Development · Aug 14, 2007 – Aug 14, 2007 · Past |
| Mark J. Keeley | Chief Financial Officer · Since at least Nov 5, 2026 |
| Mary Beth Lewis | Director · Feb 13, 2009 – Jun 8, 2017 · Past |
| Michael Gottlieb | Director · Nov 26, 2019 – Nov 26, 2019 · Past |
| Peter Cicala | Director · Since at least Nov 5, 2026 |
| Ram Krishnan | CEO, Director · Mar 19, 2018 – Aug 27, 2019 · Past |
| Richard W Wagner | Director · Jul 6, 2023 – Jul 14, 2023 · Past |
| Robert Pierce | Chief Scientific Officer · Since at least Oct 22, 2026 |
| Ronald Guido | See Remarks · Mar 25, 2021 – Mar 25, 2021 · Past |
| Sanjeev Luther | President and CEO · Since at least Jan 1, 2024 |
| Steve Mitgang | Director · Aug 1, 2010 – Jun 7, 2019 · Past |
| William A Wexler | Director · Since at least Jun 5, 2022 |
| Yiannis Monovoukas | Director · Mar 25, 2021 – Mar 25, 2021 · Past |
Log in to ask 6ix AI your own questions about Ernexa Therapeutics Inc.